[{"indications": "Indications\u00a0leishmaniasis", "name": "SODIUM STIBOGLUCONATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.4 Antiprotozoal drugs", "5.4.5 Leishmaniacides", "SODIUM STIBOGLUCONATE"], "cautions": "Cautions\u00a0intravenous injections must be given\r\nslowly over 5 minutes (to reduce risk of local thrombosis) and stopped\r\nif coughing or substernal pain; mucocutaneous\r\ndisease (see below); monitor ECG before\r\nand during treatment; heart disease (withdraw if conduction disturbances occur); treat intercurrent infection (e.g. pneumonia)Mucocutaneous disease\u00a0Successful treatment of mucocutaneous leishmaniasis may induce severe\r\ninflammation around the lesions (may be life-threatening if pharyngeal\r\nor tracheal involvement)\u2014may require corticosteroid", "side-effects": "Side-effects\u00a0anorexia, nausea, vomiting, abdominal pain, diarrhoea;\r\nECG changes; coughing (see Cautions); headache, lethargy; arthralgia,\r\nmyalgia; rarely jaundice, flushing, bleeding from\r\nnose or gum, substernal pain (see Cautions), vertigo, fever, sweating,\r\nand rash; also reported pancreatitis and anaphylaxis; pain and thrombosis\r\non intravenous administration, intramuscular injection also painful", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4050.htm", "doses": ["See notes above"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]